Vinflunine in the treatment of advanced bladder cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin.59(4), 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer46(4), 765–781 (2010).
   PubMed Web of Science ®Google Scholar
• Parkin DM. The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl.218, 12–20 (2008).
   PubMedGoogle Scholar
• Stein JP, Lieskovsky G, Cote R. Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. J. Clin. Oncol.10(7), 1066–1073 (1992).
   PubMed Web of Science ®Google Scholar
• Von der Maase H, Andersen L, Crino L et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a Phase II clinical trial. Ann. Oncol.10(12), 1461–1465 (1999).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.17(9), 2876–2881 (1999).
   PubMed Web of Science ®Google Scholar
• Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol.18(9), 1921–1927 (2000).
   PubMed Web of Science ®Google Scholar
• von der Maase H, Sengelov L, Roberts JT et al. Long term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol.23(21), 4602–4608 (2005).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized Phase II trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol.19(10), 2638–2648 (2001).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, von der Maase H, Mead GM et al. Randomized Phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC30987/Intergroup study. Proc. Am. Soc. Clin. Oncol.25(Suppl. 18), (2007) (Abstract LBA5030).
   PubMed Web of Science ®Google Scholar
• Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cnacer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol.18(17), 2068–2077 (2000).
   Google Scholar
• Tu SM, Hossan E, Amato R et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J. Urol.154(5), 1719–1722 (1995).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Williams SD, Finch DE et al. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer86(3), 514–518 (1999).
   PubMed Web of Science ®Google Scholar
• De Mulder PH, Theodore C, Sella A et al. Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-a as second-line treatment of adcanced transitional cell cancer of the urothelial tract. Ann. Oncol.11(11), 1391–1394 (2000).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Calabro F, Pizzocaro G et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer92(12), 2993–2998 (2001).
   PubMed Web of Science ®Google Scholar
• Meluch AA, Greco FA, Burris HA et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minnie pearl cancer research network. J. Clin. Oncol.19(12), 3018–3024 (2001).
   PubMed Web of Science ®Google Scholar
• Krege S, Rembrink V, Borgermann C et al. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a Phase 2 study. J. Urol.165(1), 67–71 (2001).
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Millikan RE, Tu SM et al. Cisplatin, gemcitabine, ifosfamide as weekly therapy: a feasibility and Phase II study of salvage treatment for advanced transitional cell carcinoma. J. Clin. Oncol.20(13), 2965–2970 (2002).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Autorino R, Giordano A et al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J. Clin. Oncol.34(12), 747–750 (2004).
   PubMed Web of Science ®Google Scholar
• Vaishampayan UN, Faulkner JR, Small EJ et al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer104(8), 1627–1632 (2005).
   PubMed Web of Science ®Google Scholar
• Fechner G, Siener R, Reimann M et al. Randomised Phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int. J. Clin. Pract.60(1), 27–31 (2006).
   PubMed Web of Science ®Google Scholar
• Kouno T, Ando M, Yonemori K et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur. Urol.52(4), 1115–1122 (2007).
   PubMed Web of Science ®Google Scholar
• Lin CC, Hsu CH, Huang CY et al. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a Phase II study. Anticancer Drugs.18(4), 487–491 (2007).
   PubMed Web of Science ®Google Scholar
• Soga N, Onishi T, Arima K et al. Paclitaxel carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int. J. Urol.14(9), 828–832 (2007).
   PubMed Web of Science ®Google Scholar
• Han KS, Joung JY, Kim TS et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br. J. Cancer98(1), 86–90 (2008).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Montesarchio V, Autorino R et al. Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. Cancer115(3), 517–523 (2009).
   PubMed Web of Science ®Google Scholar
• Suyama T, Ueda T, Fukasawa S et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J. Clin. Oncol.39(4), 244–250 (2009).
   PubMed Web of Science ®Google Scholar
• Albers P, Park SI, Niegisch G et al. Randomized Phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol. DOI: 10.1093/annonc/mdq398 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Ngan VK, Bellman K, Hill BT et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol. Pharmacol.60(18), 5045–5051 (2001).
   Google Scholar
• Kruczynski A, Colpaert F, Tarayre JP et al. Preclinical in vivo antitumor activity of Vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother. Pharmacol.41, 437–447 (1998).
   PubMed Web of Science ®Google Scholar
• Hill BT, Fiebig HH, Waud WR et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur. J. Cancer35(3), 512–520 (1999).
   PubMed Web of Science ®Google Scholar
• Bonfil RD, Russo DM, Binda MM et al. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol. Oncol.7(4), 159–166 (2002).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Delgado FM, George C. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Semin. Oncol.35(3), 534–543 (2008).
   Google Scholar
• Culine S, Theodore C, De Santis M et al. A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br. J. Cancer94(10), 1395–1401 (2006).
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Srinivas S, Stadler WM et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large Phase 2 study. Cancer115(18), 4110–4117 (2009).
   PubMed Web of Science ®Google Scholar
• Bellmunt K, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol.27(27), 4454–4461 (2009).
   PubMed Web of Science ®Google Scholar
• Pearce HL. Medicinal chemistry of bisindole alkaloids from Catharanthus. In: The Alkaloids – Antitumor Bisindole Alkaloids from Catharanthus roseus. Brossi A, Suffness M (Eds). Academic Press, CA, USA, 145 (1990).
   Google Scholar
• Fahy J, Duflos A, Ribert JP et al.Vinca alkaloids in superacidic media: a method for creatining a new family of antitumor derivatives. J. Am. Chem. Soc.119, 8576–8577 (1997).
   Web of Science ®Google Scholar
• Barnett CJ, Cullinan GJ, Gerzon K et al. Structure–activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate. J. Med. Chem.21(1), 88–96 (1978).
   PubMed Web of Science ®Google Scholar
• Kruczynski A, Barret JM, Etievant C et al. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem. Pharmacol.55(5), 635–648 (1998).
   PubMed Web of Science ®Google Scholar
• Ngan VK, Bellman K, Panda D et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res.60(18), 5045–5051 (2000).
   PubMed Web of Science ®Google Scholar
• Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol. Cancer Ther.2(5), 427–436 (2003).
   PubMed Web of Science ®Google Scholar
• Kruczynski A, Poli M, Dossi R et al. Anti-angiogenic, vascular disrupting and anti-metastatic activities of vinflunine, the latest vinka alkaloid in clinical development. Eur. J. Cancer42(16), 2821–2832 (2006).
   PubMed Web of Science ®Google Scholar
• Lobert S, Fahy J, Hill BT et al.Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L 1210 cell line. Biochemistry39(39), 12053–12062 (2000).
   PubMed Web of Science ®Google Scholar
• Jordan MA, Horwitz SB, Lobert S et al. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine. Semin. Oncol.35(3 Suppl. 3), S6–S12 (2008).
   Google Scholar
• Jean-Decoster C, Brichese L, Barret JM et al. Vinflunine, a new Vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anticancer Drugs.10(6), 537–543 (1999).
   PubMed Web of Science ®Google Scholar
• Etievant C, Kruczynski A, Barret JM et al. Markedly diminished drug resistance-inducing properties of vinflunine (20´,20´-difluoro-3´,4´-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother. Pharmacol.48(1), 62–70 (2001).
   PubMed Web of Science ®Google Scholar
• Bennouna J, Fumoleau P, Armand JP et al. Phase I and pharmacokinetic study of the new Vinca alkaloid vinflunine administered as a 10 minute infusion every 3 weeks in patients with advanced solid tumours. Ann. Oncol.14(4), 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson P, Geldart T, Fumoleau P et al. Phase I study of vinflunine administered as a 10 minute infusion on days 1 and 8 every 3 weeks. Invest. New Drugs24(3), 223–231 (2006).
   PubMed Web of Science ®Google Scholar
• Focan CN, Van Heugen J-C, Kreutz F et al. Vinflunine metabolism and disposition in cancer patients. Proc. Am. Soc. Clin. Oncol.21 (2002) (Abstract 495).
   Google Scholar
• Paule, B. Saliba F, Gil-Delgado M et al. Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): pharmacokinetic results. ASCO Meeting Abstracts (2007) (Abstract 2523).
   Google Scholar
• Bajorin DF, Dodd PM, Mazumdar M et al. Long term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol.17(10), 3173–3181 (1999).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol.28(11), 1850–1855 (2010).
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Swanson PE, Jaszcz W et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am. J. Clin. Pathol.101(2), 166–176 (1994).
   PubMed Web of Science ®Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitbaine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter Phase II National Cancer Institute trial. J. Clin. Oncol.25(16), 2218–2224 (2007).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer115(18), 4090–4095 (2009).
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J. Clin. Oncol.28(8), 1373–1379 (2010).
   PubMed Web of Science ®Google Scholar
• Bradley D, Daignault S, Smith DC et al. Maintenance sunitinib postchemotherapy in patients with adcanced urothelial carcinoma: a randomized placebo controlled Phase II trial. J. Clin. Oncol.27(Suppl. 15), (2009) (Abstract 5073).
   PubMedGoogle Scholar
• Witte RS, Elson P, Bono B et al. Eastern Cooperative Oncology Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol.15(2), 589–593 (1997).
   PubMed Web of Science ®Google Scholar
• Lorusso V, Pollera CF, Antimi M et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer34(8), 1208–1212 (1998).
   PubMed Web of Science ®Google Scholar
• McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol.15(5), 1853–1857 (1997).
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Manola J, Dreicer R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer95(5), 1022–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol.24(21), 3451–3457 (2006).
   PubMed Web of Science ®Google Scholar
• Winquist E, Vokes E, Moore MJ et al. A Phase II study of oxaliplatin in urothelial cancer. Urol. Oncol.23(3), 150–154 (2005).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Li S, Manola J et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer110(4), 759–763 (2007).
   PubMed Web of Science ®Google Scholar
• Wülfing C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label Phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer115(13), 2881–2890 (2009).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Halabi S, Sanford BL et al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann. Oncol.19(5) 946–950 (2008).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr et al. Results of the Southwest Oncology Group Phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU105(3), 317–321 (2010).
   PubMed Web of Science ®Google Scholar